关于持股 5%以上股东股份质押展期的公告 证券代码：603351 证券简称：威尔药业 公告编号：2026-003 南京威尔药业集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京威尔药业集团股份有限公司（以下简称"公司"）近日获悉公司 5%以上股东 吴仁荣先生所持有的公司股份质押展期，具体情况如下： 二、股东累计质押股份情况 注：上表中合计比例存在尾差系四舍五入所致。 特此公告。 南京威尔药业集团股份有限公司董事会 2026 年 3 月 26 日 截至公告披露日，公司控股股东及其一致行动人累计质押股份如下： | | | | | | | | | | | 单位：股 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 已质押股份 | | 未质押股份 | | | | | | | | | | 情况 | | 情况 | | | 股东 | 持股 | 持股 | 本次披露前 | 本次披露后 | 占其所 | 占公 ...

二、股东累计质押股份情况 证券代码：603351 证券简称：威尔药业 公告编号：2026-002 南京威尔药业集团股份有限公司 关于持股5%以上股东股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京威尔药业集团股份有限公司（以下简称"公司"）近日获悉公司 5%以上股东 吴仁荣先生所持有的公司股份质押，具体情况如下： 南京威尔药业集团股份有限公司董事会 2026 年 3 月 18 日 截至公告披露日，公司控股股东及其一致行动人累计质押股份如下： | | | | | | | | | | | 单位：股 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 已质押股份 | | 未质押股份 | | | | | | | | | | 情况 | | 情况 | | | 股东 | 持股 | 持股 | 本次披露前 | 本次披露后 | 占其所 | 占公司 | 已质押 | 已质押 | 未质押 | 未质押 | | | | ...

Summary of Key Points Core Viewpoint - 威尔药业 announced a plan for a concentrated auction reduction of shares by its employee stockholding platform, 舜泰宗华, which holds approximately 6.49% of the company's total shares [1]. Group 1: Share Reduction Plan - 舜泰宗华 plans to reduce its holdings by up to 446,340 shares, representing no more than 0.33% of the total share capital, between March 23 and April 10, 2026 [1]. - The estimated value of the planned reduction is approximately 12.30 million yuan, based on the closing price of 27.55 yuan per share on February 26 [1]. Group 2: Shareholding Structure - 舜泰宗华 is managed by 吴仁荣, who is also an executive partner, and is considered a concerted actor with 高正松 and 陈新国 [2]. - As of the latest announcement, 舜泰宗华 has reduced its holdings by 1,354,291 shares, with a total remaining of 8,788,699 shares [2]. Group 3: Company Financials and History - 威尔药业 was listed on the Shanghai Stock Exchange on January 30, 2019, with an initial public offering of up to 16.67 million shares at a price of 35.50 yuan per share, raising a total of approximately 591.67 million yuan [2]. - The net proceeds from the IPO were approximately 538.50 million yuan, allocated for the establishment of a production base for injectable drug excipients and to supplement working capital [2]. Group 4: Bond Issuance Update - The Shanghai Stock Exchange announced the termination of the review for 威尔药业's issuance of convertible bonds to unspecified investors, which was intended to raise up to 306 million yuan [3]. - The underwriting institution for the bond issuance was 中国银河证券, with representatives段然 and 夏沛沛 [3].

Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Nanjing Weier Pharmaceutical Group Co., Ltd., indicating a strategic move to liquidate a portion of their holdings while ensuring that the controlling shareholders will not reduce their stakes [3][10]. Group 1: Major Shareholder Information - Nanjing Shuntai Zonghua Venture Investment Partnership (Limited Partnership) holds 8,788,699 shares, representing approximately 6.49% of the total share capital of the company [2]. - The shares held by Shuntai Zonghua were acquired prior to the initial public offering and through capital reserve conversion [2]. Group 2: Share Reduction Plan Details - The planned reduction will occur from March 23, 2026, to April 10, 2026, with a maximum of 446,340 shares to be sold, equating to no more than 0.33% of the total share capital [3][5]. - The reduction does not include shares held indirectly by the controlling shareholders, ensuring their stakes remain intact during this period [3][6]. Group 3: Management Commitments - Senior management, including Vice President Zou Jianguo, has committed to not exceeding a 25% transfer of their total shareholdings during their tenure, with additional restrictions upon leaving the company [9]. - The management's commitments align with previously disclosed promises regarding shareholding and transfer limits [9].

证券代码：603351 证券简称：威尔药业 公告编号：2026-001 南京威尔药业集团股份有限公司 关于股东集中竞价减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 | 股东名称 | 南京舜泰宗华创业投资合伙企业（有限合伙） | | | | | | --- | --- | --- | --- | --- | --- | | 计划减持数量 | 不超过：446,340 股 | | | | | | 计划减持比例 | 不超过：0.33% | | | | | | 减持方式及对应减持数量 | 集中竞价减持，不超过：446,340 股 | | | | | | 减持期间 | 年 月 日 2026 3 23 4 | 日～2026 | 年 | 月 | 10 | | 拟减持股份来源 | 首次公开发行前持有及上市后资本公积转增股本取得 | | | | | | 拟减持原因 | 股东资金需求 | | | | | 南京舜泰宗华创业投资合伙企业（有限合伙）（以下简称"舜泰宗华"）为南 京威尔药 ...

Core Viewpoint - On February 26, Tianhao Energy disclosed its stock repurchase commitment, while ten A-share listed companies announced their plans for share reductions [1][2]. Group 1: Stock Repurchase and Increase - Tianhao Energy has obtained a commitment letter for a special loan for stock repurchase from a full融机构 [2]. Group 2: Share Reduction Announcements - Mengjie Co., Ltd. plans for shareholder Li Jianwei to reduce no more than 0.43% of shares [2]. - Hongsheng Huayuan's shareholders, Guo Xin Jian Yuan and Jianxin Investment, intend to collectively reduce no more than 1% of shares [2]. - Founder Technology's shareholder, Founder Information Industry, plans to reduce no more than 3% of shares [2]. - Tongguang Cable's controlling shareholder, Tongguang Group, and Chairman Zhang Zhong plan to reduce no more than 3.021% of shares [2]. - Wu Zhi Machinery's shareholder, Miao Shilei Qun, intends to reduce no more than 0.11% of shares [2]. - Qusleep Technology's shareholder, Li Liang, plans to reduce no more than 1.4% of shares [2]. - Yinhai Electronics' controlling shareholder, Yinhai Electronics Group Investment Co., Ltd., intends to reduce no more than 0.81% of shares [2]. - Weier Pharmaceutical's shareholder, Shuntai Zonghua, plans to reduce no more than 0.33% of shares [2]. - Shengyi Technology's shareholders, Guangxin Group and Chen Renxi, have completed their reduction plan [2].

Core Viewpoint - On February 26, Tianhao Energy disclosed its stock repurchase commitment, while ten A-share listed companies announced their plans for share reduction, indicating a mixed sentiment in the market [1][3]. Group 1: Stock Buyback and Reduction Announcements - Tianhao Energy has obtained a commitment letter for a stock repurchase from a full融 institution [2]. - The following companies announced share reductions: - Mengjie Co., Ltd.: Shareholder Li Jianwei plans to reduce holdings by no more than 0.43% [5]. - Hongsheng Huayuan: Shareholders Guo Xin Jian Yuan and Jianxin Investment plan to collectively reduce holdings by no more than 1% [5]. - Founder Technology: Shareholder Founder Information Industry plans to reduce holdings by no more than 3% [5]. - Tongguang Cable: Controlling shareholder Tongguang Group and Chairman Zhang Zhong plan to reduce holdings by no more than 3.021% [5]. - Wu Zhi Machinery: Director Lei Qun plans to reduce holdings by no more than 0.11% [5]. - Qusleep Technology: Shareholder Li Liang plans to reduce holdings by no more than 1.4% [5]. - Xinyaqiang: Shareholders Hongta Innovation and Sun Xiujie plan to collectively reduce holdings by no more than 4% [5]. - Galaxy Electronics: Controlling shareholder Galaxy Electronics Group Investment Co., Ltd. plans to reduce holdings by no more than 0.81% [5]. - Weier Pharmaceutical: Shareholder Shuntai Zonghua plans to reduce holdings by no more than 0.33% [5]. - Shengyi Technology: Guangxin Group and Chen Renxi have completed their reduction plan [5]. Group 2: Market Signals - The formation of a MACD golden cross signal indicates a positive trend for certain stocks, suggesting potential upward movement in the market [3].

Core Viewpoint - Weir Pharmaceuticals (603351.SH) announced that Shuntai Zonghua plans to reduce its shareholding by a maximum of 446,300 shares, which accounts for 0.33% of the company's total share capital, through centralized bidding from March 23 to April 10, 2026 [1] Summary by Category - **Company Actions** - Shuntai Zonghua intends to reduce its stake in Weir Pharmaceuticals by up to 446,300 shares [1] - The reduction represents 0.33% of the total share capital of the company [1] - **Timeline** - The share reduction is scheduled to take place between March 23 and April 10, 2026 [1]

Core Viewpoint - The recent financial report of Weir Pharmaceutical (603351) indicates modest growth in revenue and net profit for the first three quarters of 2025, reflecting the company's stable performance amidst market conditions [1] Financial Performance - The company achieved a revenue of 1.018 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 1.79% [1] - The net profit attributable to shareholders reached 114 million yuan, showing a year-on-year growth of 1.03% [1] Corporate Activities - Weir Pharmaceutical held a shareholders' meeting on December 16, 2025, to review relevant proposals [1] - The schedule for the 2026 annual shareholders' meeting has not yet been announced [1] - No specific major events for 2026 have been disclosed in recent public information, indicating a need for investors to monitor upcoming regular reports and official announcements [1]

Group 1 - The Shanghai Composite Index is at 4108.66 points, slightly down by 0.42%, with a total trading volume of 23623.15 billion yuan [1] - A total of 43 A-shares have surpassed their annual line today, with notable stocks showing significant deviation rates including Guangming Real Estate at 8.90%, Shenyu Co. at 6.99%, and Keheng Co. at 6.61% [1] - The stocks that have just crossed the annual line with smaller deviation rates include Ruipu Biotech, Yingtai Biotech, and Shanghai Phoenix [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Guangming Real Estate: 10.09% increase, trading at 3.82 yuan, with a deviation rate of 8.90% [1] - Shenyu Co.: 11.58% increase, trading at 43.08 yuan, with a deviation rate of 6.99% [1] - Keheng Co.: 11.72% increase, trading at 14.11 yuan, with a deviation rate of 6.61% [1] - Other notable stocks with significant increases include: - Shanghai Ailuo: 5.92% increase, trading at 9.31 yuan, with a deviation rate of 5.53% [1] - Lingpai Technology: 11.44% increase, trading at 31.47 yuan, with a deviation rate of 3.93% [1]